SHShamil Haroon

Shamil Haroon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shamil Haroon has a total of 347 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient-reported outcomes and immunology to targeted therapies (TLC) - COV-LT-0013

    by Shamil Haroon, Janet Lord, Elizabeth Sapey, Steven Marwaha, Sarah Hughes, Puja Myles, Louise Jackson, Tom Marshall, Christel McMullan, Lee Aiyegbusi, et al.

    Plain English Summary Aims: The project aimed to understand long COVID by studying a diverse group of people, collecting their health experiences, identifying different symptom patterns, and reviewing non-drug treatments. We also developed a digital clinical trial platform to test these treatments. Approach: We used various research methods, including reviewing existing studies, developing a questionnaire to measure symptoms, analysing health records to find common symptoms and risk factors, and involving patients in designing and testing the study. Patients helped shape the study, ensuring it was relevant and user-friendly. Findings: We found that long COVID symptoms are varied, with fatigue, brain fog, and shortness of breath being common. We created and validated a new questionnaire to measure these symptoms accurately, known as the Symptom Burden Questionnaire for Long COVID (SBQ TM -LC). Our study of health records identified 62 long COVID symptoms and highlighted that women and people with certain health conditions are more at risk. We also found three groups of people with long COVID – those with a broad range of symptoms, those with mainly respiratory symptoms, and those with mental health and cognitive symptoms. Few studies on non-drug treatments exist, showing a need for more research. Patients played a key role in designing our study, and we produced checklists describing how to involve and engage patients in research. However, our digital trial faced challenges like recruitment difficulties. Conclusions and recommendations: Long COVID is a complex condition with three main symptom patterns, which are important for designing treatments and care. Our new patient-reported outcome measure, the SBQ TM -LC, can help in research and clinical settings. More high-quality studies on non-drug treatments are needed, and new methods are needed to conduct effective digital trials. Patient involvement is crucial for relevant research, and our checklists can help future studies better involve patients. Executive Summary Study aims: The project aimed to establish a representative population-based cohort of individuals with long COVID and collect patient-reported outcomes (PROs) to gain comprehensive insights into the lived experience of people with the condition. We also sought to identify and confirm distinct long COVID phenotypes to enhance our understanding of its diverse manifestations. Furthermore, the project aimed to review potential non-pharmacological therapies to identify potential interventions. Finally, in collaboration with stakeholders, the project aimed to co-produce a clinical trial platform and evaluate the feasibility of conducting a digital, decentralised trial of non-pharmacological interventions to improve long COVID symptoms. Background: Long COVID, a condition of significant importance due to its high prevalence and heterogeneity, presents substantial challenges to society and healthcare. Its complexity stems from the likely existence of several symptom clusters or phenotypes, complicating efforts to develop a universal case definition. Additionally, the absence of specific patient-reported outcome measures hinders the ability to assess and address patient needs accurately. There is an urgent need for evidence-based therapies, including non-pharmacological treatments, to manage long COVID effectively. To achieve this, it is important to establish a clinical trial platform to evaluate therapies rigorously, alongside assessing the platform's feasibility to deliver decentralised trials. Methods: The project employed several research methods to achieve the aims and objectives. This included: A systematic review analysed pooled prevalence data to examine the varied symptoms of long COVID. This included an extensive literature search to identify relevant studies, followed by a meta-analysis to aggregate the prevalence of different long COVID symptoms such as fatigue, cognitive dysfunction, and anxiety. Rasch analysis was used to develop and validate a novel patient-reported outcome measure, the Symptom Burden Questionnaire for Long COVID (SBQ TM -LC) . We conducted field tests to refine the questionnaire, ensuring it had robust psychometric properties. This method involved iterative testing and analysis to confirm that the scales used were reliable and valid for measuring the symptom burden in adults with long COVID. A large-scale retrospective matched cohort study was conducted using the UK's Clinical Practice Research Datalink (CPRD) Aurum database. It included 486,149 non-hospitalised individuals with confirmed SARS-CoV-2 infection and 1,944,580 matched controls. The study aimed to identify long-term symptoms associated with SARS-CoV-2 infection beyond 12 weeks, employing Cox proportional hazards models to estimate adjusted hazard ratios for 115 individual symptoms. The analysis also explored demographic and clinical risk factors for developing long COVID and characterised dominant symptom clusters. A systematic review summarised the evidence on non-pharmacological therapies for post-viral syndromes, including long COVID. We conducted extensive literature searches across multiple databases, followed by data extraction and synthesis. The analysis included assessing the risk of bias and effectiveness of interventions in included studies, aiming to provide evidence-based recommendations for managing long COVID symptoms. A co-production approach involved patients with long COVID and other stakeholders in co-designing and evaluating a feasibility platform trial of pacing interventions. Methods included conducting a consensus workshop for research prioritisation, systematic identification, and review of potential pacing resources and weekly collaborative meetings to co-design study processes, materials, and a digital trial platform. This process ensured the interventions were patient-centred and feasible for a decentralised digital trial. A mixed methods feasibility...

  • Open Access

    Patient Perceptions of Artificial Intelligence–Supported Shared Decision-Making in UK Primary Care for Multiple Long-Term Conditions: Qualitative Study

    by Charlotte Spurway, Sarah Flanagan, Jenny Cooper, Francesca L Crowe, Shamil Haroon, Tom Marshall, Leah Fitzsimmons, Eleanor Hathaway, Krishnarajah Nirantharakumar, Thomas Jackson, et al.

    Background: The prevalence of multiple long-term conditions (MLTCs) is increasing globally, leading to complex health care needs and polypharmacy. Shared decision-making (SDM) is important for supporting patient-centered care, yet barriers such as limited consultation time, discontinuity of care, and communication challenges hinder implementation. Artificial intelligence (AI) has the potential to support SDM by providing personalized, data-driven recommendations, particularly for medication management in patients with MLTCs. Objective: This study aimed to explore the perspectives of patients with MLTCs regarding SDM with their general practitioners (GPs) and to explore patients’ views about the use of an AI tool to support SDM, particularly in relation to prescribing decisions. Methods: This qualitative study explored the perspectives of 18 patients with MLTCs on SDM and the use of an AI tool prototype during GP consultations. Semistructured interviews used a simulated patient vignette and a visual AI tool dashboard to facilitate discussion. Participants were recruited through GP practices via the Clinical Practice Research Datalink and community-based organizations across the West Midlands. The data were then analyzed using thematic analysis. Results: Two overarching categories were identified: SDM in GP consultations and the AI tool for SDM. Within SDM, themes included communication and collaboration and system-level barriers, such as limited consultation time, lack of continuity, and fragmented records. Within the AI tool category, themes were related to practical design and implementation, implications for clinical practice and decision-making, and perceived risks and limitations. Participants valued the tool’s potential to summarize health information and support discussions but highlighted the need for clear explanations, accessible design, and clinician guidance. Concerns included time pressures, depersonalization, trust, and transparency, with participants emphasizing that AI should support rather than replace clinical judgment. Conclusions: Overall, patients perceived AI as a promising way to enhance SDM by improving communication and collaboration between patient and clinician. However, patients also had concerns about the accuracy and veracity of AI. The study provides recommendations for AI tools in GP consultations, emphasizing clear, accessible outputs and the use of lay language. AI tools should enhance rather than replace clinical judgment, be transparent about data sources, and be developed with diverse patient input to ensure inclusivity and usability, particularly for those with MLTCs.


  • Open Access

    Self-management of long COVID symptoms with over-the-counter medicines and other non-prescribed therapies: a cross-sectional survey

    by Naijie Guan, Grace Turner, Richard Hotham, Daniel Lange, Kirsty R. Brown, Christel McMullan, Sarah E. Hughes, Olalekan Lee Aiyegbusi, Karen Matthews, Louise Jackson, et al.

    Background: The high prevalence of long COVID globally necessitates investigation into its self-management, especially given the absence of definitive and effective treatments and uneven access to healthcare services. Methods: This study surveyed the use of over-the-counter (OTC) medicines, supplements, remedies, and other non-prescription therapies for managing long COVID symptoms in the UK. It aimed to identify the range of treatments used for self-management, explore the sources of these treatments, factors influencing treatment choices, and associated out-of-pocket expenses. A cross-sectional electronic survey was provided to individuals experiencing long COVID. It included questions on the use of OTC medications, supplements, and other therapies, where they were sourced, decision-making influences, and financial costs. Descriptive statistics and thematic analysis were applied to analyse the data. Results: Among the 193 surveyed participants, significant use of vitamins, minerals, and herbal treatments (88.8%), and analgesics (73.6%) was reported, with 42% exceeding recommended dosages. Some participants sought relief through alternative therapies such as physiotherapy and acupuncture, often incurring significant personal expenses. Choices about self-management were influenced by medical professionals, family, friends, and online sources, including support groups and social media. Conclusions: People with long COVID may access a wide range of OTC medicines, dietary supplements, herbal remedies, and non-pharmacological therapies to self-manage symptoms. Healthcare providers should be aware of the use of non-prescribed therapies among long COVID sufferers and consider these in their treatment plans. Public health policies should focus on providing accurate information and guidance for patients self-managing long COVID symptoms.

  • Open Access

    Exploring Patient Perspectives on the Use of Artificial Intelligence to Inform Joint Decision-Making for Patients With Multiple Conditions in Primary Care in the United Kingdom: Qualitative Study

    by Sarah Flanagan, Charlotte Spurway, Louise Jackson, Jenny Cooper, Francesca L Crowe, Shamil Haroon, Tom Marshall, Leah Fitzsimmons, Eleanor Hathaway, Krishnarajah Nirantharakumar, et al.

    Background: Multimorbidity, living with 2 or more long-term health conditions, is increasing globally and now affects over one-quarter of adults in England. People with multiple long-term conditions (MLTC) face complex health and treatment challenges, often experiencing fragmented care within systems oriented toward single-disease management. Artificial intelligence (AI) has the potential to support clinicians and patients by analyzing complex health data, optimizing treatment strategies, and predicting disease trajectories. Objective: The OPTIMAL (Optimizing Therapies, Disease Trajectories, and AI-Assisted Clinical Management for Patients Living with Complex Multimorbidity) project aims to develop AI-enabled tools to support shared decision-making in primary care. This study explored how patients with MLTC perceive the use of AI to inform joint decision-making in primary care. Methods: Semistructured interviews were conducted via telephone or video call with 29 adults living with MLTC between July and November 2023. Participants were recruited through general practitioner practices via the Clinical Practice Research Datalink and community-based organizations across the West Midlands. Interviews were transcribed verbatim and analyzed thematically using an inductive approach. Members of a patient advisory group were involved in developing study materials, refining the interview guide, and reviewing emerging findings to ensure relevance and authenticity. Results: Participants identified potential benefits of AI in enhancing consultation efficiency and accuracy, improving access to information for patients and clinicians, promoting early detection of health changes, and reducing health care inequalities. However, concerns were raised about the loss of human interaction, data privacy and security, transparency of algorithms, and the potential for bias and inequity in AI systems. Trust and acceptance varied by age and familiarity with technology. Some participants expressed uncertainty about what AI entails and how it could be used in primary care. Conclusions: Patients with MLTC viewed AI-assisted decision-making in primary care with cautious optimism. While many recognized potential benefits for coordination and personalization of care, others expressed reservations about privacy, fairness, and the risk of diminished human connection.


  • Open Access

    Perceptions of an AI-based clinical decision support tool for prescribing in multiple long-term conditions: a qualitative study of general practice clinicians in England

    by Alexander D’ELia, Simon George Morris, Jennifer Cooper, Krishnarajah Nirantharakumar, Thomas Jackson, Tom Marshall, Leah Fitzsimmons, Louise J Jackson, Francesca Crowe, Shamil Haroon, et al.

    Background: Artificial intelligence (AI)-based clinical decision support systems (CDSSs) are currently being developed to aid prescribing in primary care. There is a lack of research on how these systems will be perceived and used by healthcare professionals and subsequently on how to optimise the implementation process of AI-based CDSSs (AICDSSs). Objectives: To explore healthcare professionals’ perspectives on the use of an AICDSS for prescribing in co-existing multiple long-term conditions (MLTC), and the relevance to shared decision making (SDM). Design: Qualitative study using template analysis of semistructured interviews, based on a case vignette and a mock-up of an AICDSS. Setting: Healthcare professionals prescribing for patients working in the English National Health Service (NHS) primary care in the West Midlands region. Participants: A purposive sample of general practitioners/resident doctors (10), nurse prescribers (3) and prescribing pharmacists (2) working in the English NHS primary care. Results: The proposed tool generated interest among the participants. Findings included the perception of the tool as user friendly and as a valuable complement to existing clinical guidelines, particularly in a patient population with multiple long-term conditions and polypharmacy, where existing guidelines may be inadequate. Concerns were raised about integration into existing clinical documentation systems, medicolegal aspects, how to interpret findings that were inconsistent with clinical guidelines, and the impact on patient-prescriber relationships. Views differed on whether the tool would aid SDM. Conclusion: AICDSSs such as the OPTIMAL tool hold potential for optimising pharmaceutical treatment in patients with MLTC. However, specific issues related to the tool need to be addressed and careful implementation into the existing clinical practice is necessary to realise the potential benefits.


  • Open Access

    Perspectives of Health Care Professionals on the Use of AI to Support Clinical Decision-Making in the Management of Multiple Long-Term Conditions: Interview Study

    by Jennifer Cooper, Shamil Haroon, Francesca Crowe, Krishnarajah Nirantharakumar, Thomas Jackson, Leah Fitzsimmons, Eleanor Hathaway, Sarah Flanagan, Tom Marshall, Louise J Jackson, et al.

    Background: Managing multiple long-term conditions (MLTC) is complex. Clinical management guidelines are typically focused on individual conditions and lack a robust evidence base for patients with MLTC. MLTC management is largely delivered in primary care, where health care professionals (HCPs) have identified the need for more holistic yet efficient models of care that can address patients’ medical, pharmacological, social, and mental health needs. Artificial intelligence (AI) has proven effective in tackling complex, data-driven challenges in various fields, presenting significant opportunities for MLTC care. However, its role in managing patients with multifaceted psychosocial needs remains underexplored. The implementation of AI tools in this context introduces opportunities for innovation and challenges related to clinical appropriateness, trust, and ethical considerations. Understanding HCPs’ experiences of MLTC management and the factors influencing their attitudes toward using AI in complex clinical decision-making is crucial for successful implementation. Objective: We aimed to explore the perspectives of primary care HCPs on managing MLTC and their attitudes toward using AI tools to support clinical decision-making in MLTC care. Methods: In total, 20 HCPs, including general practitioners, geriatricians, nurses, and pharmacists, were interviewed. A patient case study was used to explore how an AI tool might alter the way in which participants approach clinical decision-making with a patient with MLTC. We derived concepts inductively from the interview transcripts and structured them according to the 5 categories of the model by Buck exploring determinants of attitudes toward AI. These included the concerns and expectations that contributed to the minimum requirements for HCPs to consider using an AI decision-making tool, as well as the individual characteristics and environmental influences determining their attitudes. Results: HCPs’ perspectives on managing MLTC were grouped into three main themes: (1) balancing multiple competing factors, including accounting for patients’ social circumstances; (2) managing polypharmacy; and (3) working beyond single-condition guidelines. HCPs typically expected that AI tools would improve the safety and quality of clinical decision-making. However, they expressed concerns about the impact on the therapeutic clinician-patient relationship that is fundamental to the care of patients with MLTC. The key prerequisites for clinicians adopting AI tools in this context included improving public and patient trust in AI, saving time and integrating with existing systems, and ensuring that the rationale behind a recommendation is apparent to enable a final decision made by an experienced human clinician. Conclusions: This is the first study to examine the attitudes of HCPs toward using AI decision-making tools in the context of managing MLTC. HCPs were optimistic about AI’s potential to improve decision-making safety and quality but emphasized that the human touch remains essential for patients with complex needs. We identified critical requirements for AI adoption, including addressing patients’ perceptions, time efficiency, and the preservation of clinician and patient autonomy. International Registered Report Identifier (IRRID): RR2-10.1136/bmjopen-2023-077156


  • Open Access

    Perspectives of Health Care Professionals on the Use of AI to Support Clinical Decision-Making in the Management of Multiple Long-Term Conditions: Interview Study (Preprint)

    by Jennifer Cooper, Shamil Haroon, Francesca Crowe, Krishnarajah Nirantharakumar, Thomas Jackson, Leah Fitzsimmons, Eleanor Hathaway, Sarah Flanagan, Tom Marshall, Louise J Jackson, et al.

    BACKGROUND Managing multiple long-term conditions (MLTC) is complex. Clinical management guidelines are typically focused on individual conditions and lack a robust evidence base for patients with MLTC. MLTC management is largely delivered in primary care, where health care professionals (HCPs) have identified the need for more holistic yet efficient models of care that can address patients’ medical, pharmacological, social, and mental health needs. Artificial intelligence (AI) has proven effective in tackling complex, data-driven challenges in various fields, presenting significant opportunities for MLTC care. However, its role in managing patients with multifaceted psychosocial needs remains underexplored. The implementation of AI tools in this context introduces opportunities for innovation and challenges related to clinical appropriateness, trust, and ethical considerations. Understanding HCPs’ experiences of MLTC management and the factors influencing their attitudes toward using AI in complex clinical decision-making is crucial for successful implementation. OBJECTIVE We aimed to explore the perspectives of primary care HCPs on managing MLTC and their attitudes toward using AI tools to support clinical decision-making in MLTC care. METHODS In total, 20 HCPs, including general practitioners, geriatricians, nurses, and pharmacists, were interviewed. A patient case study was used to explore how an AI tool might alter the way in which participants approach clinical decision-making with a patient with MLTC. We derived concepts inductively from the interview transcripts and structured them according to the 5 categories of the model by Buck exploring determinants of attitudes toward AI. These included the concerns and expectations that contributed to the minimum requirements for HCPs to consider using an AI decision-making tool, as well as the individual characteristics and environmental influences determining their attitudes. RESULTS HCPs’ perspectives on managing MLTC were grouped into three main themes: (1) balancing multiple competing factors, including accounting for patients’ social circumstances; (2) managing polypharmacy; and (3) working beyond single-condition guidelines. HCPs typically expected that AI tools would improve the safety and quality of clinical decision-making. However, they expressed concerns about the impact on the therapeutic clinician-patient relationship that is fundamental to the care of patients with MLTC. The key prerequisites for clinicians adopting AI tools in this context included improving public and patient trust in AI, saving time and integrating with existing systems, and ensuring that the rationale behind a recommendation is apparent to enable a final decision made by an experienced human clinician. CONCLUSIONS This is the first study to examine the attitudes of HCPs toward using AI decision-making tools in the context of managing MLTC. HCPs were optimistic about AI’s potential to improve decision-making safety and quality but emphasized that the human touch remains essential for patients with complex needs. We identified critical requirements for AI adoption, including addressing patients’ perceptions, time efficiency, and the preservation of clinician and patient autonomy. INTERNATIONAL REGISTERED REPORT RR2-10.1136/bmjopen-2023-077156

  • Obstructive sleep apnoea syndrome and future risk of dementia among individuals managed in UK general practice

    by Jingya Wang, Anuradhaa Subramanian, Neil Cockburn, Jingyi Xiao, Krishnarajah Nirantharakumar, Shamil Haroon

    Background Obstructive sleep apnoea syndrome (OSAS) has been recognised as a potential risk factor for cognitive decline, yet its precise relationship with dementia remains uncertain. This study aimed to determine the risk of dementia among individuals with and without OSAS. Methods Data derived from 2.3 million adults (aged ≥18 years) were extracted from the Clinical Practice Research Datalink (2000–2022), a nationally representative primary care electronic health records database in the UK. 193 600 individuals with OSAS were propensity score-matched to 536 701 individuals without OSAS. Cox proportional hazard regression models were applied to quantify the risk of developing all-cause dementia, vascular dementia and Alzheimer’s disease between individuals with and without OSAS. Results With a median follow-up of 4.0 (IQR 1.8–7.5) years, 2802 and 6211 individuals developed all-cause dementia in those with and without OSAS, corresponding to crude incidence rates of 2.47 and 2.34 per 1000 person-years, respectively. The presence of OSAS was associated with higher risks of all-cause dementia (adjusted HR (aHR) 1.12, 95% CI 1.07 to 1.17), vascular dementia (1.29, 95% CI 1.19 to 1.41) and unchanged risk of Alzheimer’s disease (1.07, 95% CI 0.99 to 1.16). Individuals with OSAS who had received continuous positive airway pressure (CPAP) treatment exhibited a similar risk of all-cause dementia as their matched counterparts (0.99, 95% CI 0.74 to 1.32). Conclusion OSAS is associated with higher risks of all-cause dementia and some of its subtypes. Further investigation is needed to investigate the clinical benefits of screening for cognitive impairment in people with OSAS and to further evaluate the impact of CPAP on cognitive decline and dementia risk.


  • Opportunities and challenges for patient-reported outcome assessment in multimorbidity research and practice

    by Sarah E. Hughes, Nicola E. Anderson, Eleanor Hathaway, Christel McMullan, Benjamin M. A. Hughes, Philip Collis, John Devin Peipert, Shamil Haroon, Melanie Calvert


  • The Time to Inflammatory Bowel Disease Diagnosis for Patients Presenting with Abdominal Symptoms in Primary Care and its Association with Emergency Hospital Admissions and Surgery: A Retrospective Cohort Study

    by Nosheen Umar, Phil Harvey, Nicola J Adderley, Shamil Haroon, Nigel Trudgill

    Background: Patients with inflammatory bowel disease (IBD) presenting to primary care may experience diagnostic delays. We aimed to evaluate this and assess whether time to diagnosis is associated with clinical outcomes. Methods: A retrospective cohort study using English primary care data from January 1, 2010, to December 31, 2019, linked to hospital admission data was undertaken. Patients were followed from the first IBD-related presentation in primary care to IBD diagnosis. Associations of time to diagnosis exceeding a year were assessed using a Robust Poisson regression model. Associations between time to diagnosis and IBD-related emergency hospital admissions and surgery were assessed using Poisson and Cox proportional hazards models, respectively. Results: Of 28 092 IBD patients, 60% had ulcerative colitis (UC) and 40% had Crohn’s disease (CD). The median age was 43 (interquartile range, 30-58) years and 51.9% were female. Median time to diagnosis was 15.6 (interquartile range, 4.3-28.1) months. Factors associated with more than a year to diagnosis included female sex (adjusted risk ratio [aRR], 1.23; 95% CI, 1.21-1.26), older age (aRR, 1.05; 95% CI, 1.01-1.10; comparing >70 years of age with 18-30 years of age), obesity (aRR, 1.03; 95% CI, 1.00-1.06), smoking (aRR, 1.05; 95% CI, 1.02-1.08), CD compared with UC (aRR, 1.13; 95% CI, 1.11-1.16), and a fecal calprotectin over 500 μg/g (aRR, 0.89; 95% CI, 0.82-0.95). The highest quartile of time to diagnosis compared with the lowest was associated with IBD-related emergency admissions (incidence rate ratio, 1.06; 95% CI, 1.01-1.11). Conclusion: Longer times to IBD diagnoses were associated with being female, advanced age, obesity, smoking, and Crohn’s disease. More IBD-related emergency admissions were observed in patients with a prolonged time to diagnosis.